Article Sidebar

PDF
Date Published: 15/11/2023
Abstract Views: 114
Views PDF: 68
DOI: https://doi.org/10.51298/vmj.v531i2.7155
Issue
Vol. 531 No. 2 (2023)
Section
Các bài báo
How to Cite
Nguyễn , T. T. H. ., Vũ , H. T. ., & Nguyễn , C. H. . (2023). RESPONSE OF NEOADJUVANT CHEMOTHERAPY WITH 4AC-4P REGIMEN IN STAGE III BREAST CANCER AT BAC GIANG CANCER HOSPITAL. Vietnam Medical Journal, 531(2). https://doi.org/10.51298/vmj.v531i2.7155

RESPONSE OF NEOADJUVANT CHEMOTHERAPY WITH 4AC-4P REGIMEN IN STAGE III BREAST CANCER AT BAC GIANG CANCER HOSPITAL

Thị Thanh Huyền Nguyễn 1, Hồng Thăng Vũ 2,, Công Hoàng Nguyễn 3
1 Bacgiang Oncology Hospital
2 HMU
3 K hospital

Main Article Content

Abstract

Aims: to evaluate the response of neoadjuvant chemotherapy with 4AC-4P regimen in breast cancer stage III patients at Bac Giang Oncology Hospital. Subjects and methods: Cross-sectional study on 55 patients with stage III breast cancer who received preoperative chemotherapy with 4AC-4P regimen at Bac Giang cancer Hospital from January 2021 to June 2022. Results: The average age of the patients was 49.0 ± 9.2 years old, all patients were in stage III, in which the majority of patients in stage IIIB accounted for 56.4%. Phase IIIA, IIIC 38.2% and 5.5% respectively. Clinically completed response after 8 courses of chemotherapy reached 5.5%; 94.5% partial response. The rate of patients converting from non-surgical to operable was 70.9%. Complete response on histopathology reached 20%. Conclusion: Chemotherapy by 4AC-4P is feseable regimen for stage III breast cancer and actually confident choice in cancer hospitals in Vietnam.

Article Details

Keywords

Ung thư vú giai đoạn III, hóa trị chất tiền phẫu, phác đồ 4AC-4P

References

1. Estimated Incidence. Mortality and Prevalence Worldwide 2020
2. Nguyễn Bá Đức, Bùi Diệu, Trần Văn Thuấn và cs (2012). Gánh nặng bệnh ung thư và chiến lược phòng chống ung thư quốc gia đến năm 2020. Tạp chí Ung thư học, Hội thảo quốc gia phòng chống ung thư lần thứ XVI, Số 1 (2012), 13-19.
3. NCCN Clinical Practice Guidelines in Oncology. Version 1.2020
4. Bùi Diệu và cộng sự (2015). Dịch tễ học ung thư vú, Phẫu thuật UTV, Nhà xuất bản Y học Hà Nội
5. Eisenhauer EA, Therasse P, Bogaerts J, et al. new response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer Oxf Engl 1990. 2009;45(2):228-247.
6. Guarneri V, Broglio K, Kau S-W, et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol Off J Am Soc Clin Oncol. 2006;24(7):1037-1044.
7. Nguyễn Thị Thủy (2016). Đánh giá kết quả hóa trị bổ trợ trước phác đồ 4AC-4T trên bệnh nhân ung thư vú giai đoạn III, Luận văn thạc sỹ y học, Trường Đại học y Hà Nội
8. Hutcheon AW, Heys SD, Sarkar TK, Aberdeen Breast Group. Neoadjuvant docetaxel in locally advanced breast cancer. Breast Cancer Res Treat. 2003;79 Suppl 1: S19-24.
9. Preoperative Doxorubicin Plus Cyclophosphamide Followed by Preoperative or Postoperative Docetaxel. Accessed June 15, 2023. https://www.cancernetwork.com/view/preoperative-doxorubicin plus cyclophosphamide
10. Ngô Trường Sơn, Vũ Hồng Thăng (2021). Đánh giá kết quả hóa trị bổ trợ trước ung thư vú giai đoạn II, III ở phụ nữ mạn kinh. Y Dược học, số 31, tháng 9/2021, tr 92-5.